FDA Set To Release Biosimilars Naming Guidance, Sens. Say
Regulators at the U.S. Food and Drug Administration have drafted long-awaited guidance on how biosimilars will be named and are awaiting a decision from their superiors on whether to publish the...To view the full article, register now.
Already a subscriber? Click here to view full article